STOCK TITAN
  1. Home
  2. News
  3. BLCO

Bausch + Lomb Corporation - BLCO STOCK NEWS

Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.

Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.

Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.

Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.

Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.

With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.

News

Bausch + Lomb Completes Acquisition of XIIDRA®

Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA and other ophthalmology assets, expects to lead in prescription dry eye category. DED affects 739 million people worldwide, with the US market expected to grow at a double-digit compounded annual growth rate over the next five years. The acquisition was funded through an upfront payment of $1.75 billion in cash, with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization. XIIDRA and MIEBO are prescription eye drops used to treat dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
acquisition
-
News

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

Rhea-AI Summary
Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS, a new line of specialty eye care products. The products are hypoallergenic, clinically proven, and free from harsh ingredients. The line includes a cleansing water and makeup remover, lash & brow serum, and brightening eye cream. Clinical studies show visible improvements in skin tone, texture, and lash volume. The products are available in stores and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
News

Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

Rhea-AI Summary
Bausch + Lomb's ONE by ONE and Biotrue Eye Care Recycling programs recognized as 2023 Sustainability Award winners
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
News

Bausch + Lomb Announces Pricing of Senior Secured Notes Offering

Rhea-AI Summary
Bausch + Lomb prices $1.4 billion senior secured notes offering to fund acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
News

Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States

Rhea-AI Summary
Bausch + Lomb launches MIEBO, the first prescription eye drop targeting tear evaporation in dry eye disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News

Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)

Rhea-AI Summary
Bausch + Lomb launches $1.4 billion offering of senior secured notes and seeks to enter into an incremental term loan facility. The proceeds will fund the pending acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
acquisition
News

Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

Rhea-AI Summary
Bausch + Lomb launches $1.4 billion offering of new senior secured notes and seeks incremental term loan facility for pending acquisition of XIIDRA. Bausch + Lomb expected to borrow $500 million under the Term Loan Facility. Notes offering not conditioned upon completion of the acquisition. Closing of the Term Loan Facility and Notes offering subject to market and other conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
acquisition
-
News

Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®

Rhea-AI Summary
Bausch + Lomb discloses financial information regarding the proposed acquisition of XIIDRA and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
acquisition
-
News

Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting

Rhea-AI Summary
Bausch + Lomb announces 13 podium and poster presentations at ESCRS annual meeting, featuring surgical technologies like SeeLuma™, MIMS®, and IC-8® Apthera IOL. Educational events and networking opportunities will also be held.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
News

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

Rhea-AI Summary
Bausch + Lomb CEO to participate in 2023 Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none

FAQ

What is the current stock price of Bausch + Lomb Corporation (BLCO)?

The current stock price of Bausch + Lomb Corporation (BLCO) is $20.5 as of November 1, 2024.

What is the market cap of Bausch + Lomb Corporation (BLCO)?

The market cap of Bausch + Lomb Corporation (BLCO) is approximately 7.2B.

What does Bausch + Lomb Corporation do?

Bausch + Lomb Corporation operates in the vision care industry, offering products in vision care, surgical, and ophthalmic pharmaceuticals segments.

When did Bausch + Lomb become a public company?

Bausch + Lomb became a public company in 2022 after spinning off from Bausch Health.

What are the primary segments Bausch + Lomb operates in?

The primary segments are vision care, surgical, and ophthalmic pharmaceuticals.

What are some key products in Bausch + Lomb's vision care segment?

Key products include Biotrue and Lumify, along with various contact lenses.

What does Bausch + Lomb offer in its surgical segment?

The surgical segment includes intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments.

What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?

This segment features over 100 products, including Xipere, Vyzulta, and Lotemax, for treating various eye conditions.

Where is Bausch + Lomb Corporation headquartered?

The company is headquartered in Madrid, Spain.

What market share does Bausch + Lomb hold in the contact lenses market?

Bausch + Lomb controls 10% of the contact lenses market.

What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?

Its extensive lineup of over 100 eye care products helps Bausch + Lomb maintain a leadership position in the market.

What is Bausch + Lomb's commitment towards its products and services?

Bausch + Lomb is committed to innovation and quality, continuously enhancing its offerings through new projects and partnerships.

Stock BLCO logo
Bausch + Lomb Corporation

NYSE:BLCO

BLCO Rankings

#1035 Ranked by Market Cap
N/A Ranked by Dividends

BLCO Stock Data

7.21B
351.90M
88.49%
11.74%
0.43%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States of America
VAUGHAN